伏诺拉生在消化道出血管理中的研究进展:药理学机制、临床应用与未来方向  

Advances in the Study of Volnoxan in the Management of Gastrointestinal Bleeding: Pharmacological Mechanisms, Clinical Applications and Future Directions

作　　者：黄栋 景德怀[2] 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁医学院附属医院消化内科,山东 济宁

出　　处：《医学诊断》2024年第4期456-460,共5页Medical Diagnosis

摘　　要：消化道出血是一种严重的医疗紧急情况,影响到大量患者。传统的质子泵抑制剂(PPIs)在急性出血管理中存在起效延迟和副作用等局限性。伏诺拉生作为一种新型钾离子竞争性酸阻滞剂(P-CAB),通过快速抑制胃酸分泌,在短时间内显著降低胃内酸度,展示了在消化道出血管理中的重要性。研究表明,伏诺拉生在上消化道出血(UGIB)、非甾体抗炎药(NSAIDs)相关出血及胃食管反流病等多个领域具有良好的临床应用效果,显著降低再出血率并改善患者生活质量。此外,伏诺拉生在长期使用中表现出较低的副作用风险,尤其适合高风险患者。各国临床指南已将伏诺拉生推荐用于消化道出血的管理。未来的研究应着重于大规模随机对照试验和个体化治疗策略,以进一步验证其疗效和安全性。伏诺拉生在消化道疾病管理中的应用前景广阔,期待能为患者提供更安全有效的治疗选择。Gastrointestinal bleeding is a serious medical emergency affecting a significant number of patients. Traditional proton pump inhibitors (PPIs) have limitations in the management of acute bleeding, including delayed onset of action and various side effects. Vonoprazan, a novel potassium-competitive acid blocker (P-CAB), rapidly suppresses gastric acid secretion and significantly lowers intragastric acidity within a short time frame, demonstrating its importance in the management of gastrointestinal bleeding. Studies indicate that vonoprazan is effective in various conditions, including upper gastrointestinal bleeding (UGIB), NSAID-related bleeding, and gastroesophageal reflux disease (GERD), significantly reducing rebleeding rates and improving patients' quality of life. Additionally, vonoprazan exhibits a lower risk of side effects during long-term use, making it particularly suitable for high-risk patients. Clinical guidelines from multiple countries have recommended vonoprazan for the management of gastrointestinal bleeding. Futur

关 键 词：消化道出血 夫诺拉生 质子泵抑制剂 上消化道出血 NASIDs相关性出血 

分 类 号：R57[医药卫生—消化系统]